Hirsutism and gynaecomastia are two distinct hormonal conditions that can cause considerable distress and often signal an underlying imbalance in sex hormone levels. Hirsutism refers to excessive male-pattern hair growth in women, whilst gynaecomastia describes the benign enlargement of breast glandular tissue in men. Although they affect different sexes and present differently, both conditions can share common hormonal roots — including disorders of the adrenal glands, gonads, or the effects of certain medications. Understanding the causes, when to seek help, and what treatments are available on the NHS is essential for anyone affected by either condition.

Understanding Hirsutism and Gynaecomastia

Hirsutism is excessive male-pattern hair growth in women driven by androgen excess, whilst gynaecomastia is benign breast glandular enlargement in men caused by a relative oestrogen-to-androgen imbalance; both can reflect underlying hormonal disorders.

Hirsutism and gynaecomastia are two distinct but sometimes related conditions that can affect people at different stages of life, often causing significant distress and prompting questions about underlying health. Hirsutism refers to excessive hair growth in women in areas where hair is typically more prominent in men — such as the face, chest, abdomen, and back. It is driven by elevated levels of androgens (male sex hormones), increased sensitivity of hair follicles to these hormones, or both. Gynaecomastia describes the benign enlargement of breast glandular tissue in males (sometimes referred to colloquially as 'man boobs'). It is distinct from pseudogynaecomastia, which involves fat deposition rather than true glandular growth.

Both conditions can reflect an imbalance in sex hormone levels — androgens and oestrogens — but other factors also play a role, including obesity, certain medications, and differences in peripheral tissue sensitivity to hormones. In women, hirsutism affects approximately 5–10% of the population and is one of the most common reasons for referral to endocrinology or dermatology services (NHS). In men, gynaecomastia is surprisingly prevalent, affecting a significant proportion of adolescent boys transiently during puberty, and a notable proportion of older men.

Whilst these two conditions may seem unrelated, they can occasionally share common hormonal roots — for example, in conditions affecting the adrenal glands or gonads, or as a result of certain medications. Understanding the physiology behind each condition is the first step towards appropriate investigation and management, and neither should be dismissed as purely cosmetic without proper clinical evaluation.

Common Causes and Underlying Conditions

PCOS is the most common cause of hirsutism, whilst gynaecomastia is frequently caused by physiological changes, medications, hypogonadism, liver disease, or obesity; a full medication review is essential in both cases.

The causes of hirsutism and gynaecomastia are varied, ranging from physiological changes to significant underlying medical conditions.

For hirsutism in women, the most common cause is polycystic ovary syndrome (PCOS), which accounts for the majority of cases and is associated with elevated androgen production from the ovaries, often accompanied by irregular periods, acne, and metabolic disturbances (NICE NG88). It is important to note that mild facial or body hair in women may also reflect normal ethnic variation, particularly in those of South Asian or Mediterranean heritage. Other causes include:

• Congenital adrenal hyperplasia (CAH) — a genetic condition affecting cortisol production, leading to androgen excess

• Cushing's syndrome — caused by prolonged exposure to high cortisol levels

• Androgen-secreting tumours of the ovaries or adrenal glands (rare but important to exclude)

• Idiopathic hirsutism — where no hormonal abnormality is identified, but hair follicles show increased androgen sensitivity

For gynaecomastia, the underlying mechanism involves a relative excess of oestrogen compared to androgens. Common causes include:

• Physiological gynaecomastia — occurring in neonates, adolescents, and older men as a normal hormonal fluctuation

• Medications — a significant cause; commonly implicated drugs in the UK include spironolactone, cimetidine, anabolic steroids, some antipsychotics, certain antihypertensives, finasteride, dutasteride, antiandrogens, oestrogens, and some antiretrovirals (BNF)

• Hypogonadism — reduced testosterone production due to Klinefelter syndrome, orchitis, or age-related decline

• Liver disease (including alcohol-related liver disease) or chronic kidney disease — altering hormone metabolism

• Obesity — which increases peripheral conversion of androgens to oestrogens

• Hyperthyroidism and hyperprolactinaemia — both capable of disrupting the androgen-oestrogen balance

In some cases, both conditions may coexist in individuals with disorders of sex hormone regulation, such as adrenal tumours or differences in sex development (DSD). A thorough medical history, including a full medication review, is essential in identifying the likely cause.

When to See Your GP or an NHS Specialist

Seek GP assessment promptly if hirsutism is rapidly worsening or accompanied by virilisation, or if gynaecomastia is unilateral, hard, fixed, or associated with nipple discharge, as these features require urgent evaluation to exclude malignancy.

Knowing when to seek medical advice is important for both conditions. Whilst some degree of gynaecomastia during puberty is entirely normal and usually resolves within one to two years, there are specific circumstances where prompt assessment is warranted. Similarly, mild facial hair in women may reflect normal variation, but persistent or rapidly worsening hirsutism should always be evaluated.

You should contact your GP if you experience any of the following:

• Hirsutism that develops rapidly or is accompanied by acne, irregular or absent periods, or unexplained weight gain

• Signs of virilisation in women — such as deepening of the voice, clitoral enlargement, or male-pattern baldness — which may suggest an androgen-secreting tumour

• Gynaecomastia that is painful, tender, or associated with nipple discharge

• Breast enlargement in men that is unilateral, hard, fixed, or associated with skin or nipple changes — these features require urgent assessment to exclude breast cancer

• Gynaecomastia persisting beyond two years in adolescents, or new onset in adult men without an obvious cause

• A testicular mass, persistent testicular pain, or other testicular changes, which require urgent urology assessment to exclude testicular cancer

• Any associated symptoms such as fatigue, weight changes, reduced libido, or mood disturbance

Your GP will take a detailed history and may arrange initial blood tests before referring you to an appropriate NHS specialist — typically an endocrinologist, gynaecologist, dermatologist, or breast clinic depending on the presentation. In men with unilateral hard or fixed breast tissue, nipple discharge, or skin changes, your GP should refer you urgently to a breast clinic under the NICE NG12 two-week-wait pathway for suspected cancer. Similarly, a suspected testicular mass warrants urgent urology referral and testicular ultrasound. Early referral is particularly important when malignancy or a serious endocrine disorder is suspected. Do not delay seeking advice out of embarrassment, as both conditions are common and well understood by healthcare professionals.

Diagnosis and Tests Available on the NHS

Diagnosis begins with clinical assessment and targeted blood tests including testosterone, SHBG, LH, FSH, and prolactin; breast imaging and testicular ultrasound are arranged where malignancy is suspected, guided by NICE NG88 and NG12.

Diagnosis of both hirsutism and gynaecomastia begins with a thorough clinical assessment, including a detailed medical and medication history, family history, and physical examination. Your GP or specialist will assess the distribution and severity of hair growth using tools such as the Ferriman-Gallwey score for hirsutism, and will examine breast tissue to distinguish true gynaecomastia from pseudogynaecomastia or other pathology.

For hirsutism, the following investigations are commonly requested on the NHS:

• Total and free testosterone — to assess androgen excess

• Sex hormone-binding globulin (SHBG) — low levels increase free androgen availability

• LH and FSH — to help evaluate ovarian function; note that LH and FSH are not required to diagnose PCOS, which is based on the Rotterdam criteria

• DHEAS (dehydroepiandrosterone sulphate) — elevated levels suggest adrenal androgen excess

• 17-hydroxyprogesterone — to screen for congenital adrenal hyperplasia

• Prolactin and thyroid function tests — to exclude other contributing conditions

• HbA1c or oral glucose tolerance test (OGTT) — to screen for impaired glucose regulation or type 2 diabetes, in line with NICE NG88; routine measurement of fasting insulin is not recommended

• Pelvic ultrasound — used when diagnostic uncertainty persists or as part of the Rotterdam criteria assessment in suspected PCOS; not always required for diagnosis

For gynaecomastia, investigations typically include:

• Testosterone, LH, FSH, and oestradiol — to assess the androgen-oestrogen balance

• Prolactin and thyroid function — to exclude hyperprolactinaemia and thyroid disorders

• Liver and renal function tests — given the role of these organs in hormone metabolism

• hCG (human chorionic gonadotrophin) and AFP (alpha-fetoprotein) — to screen for testicular germ cell tumours and other hCG-secreting malignancies; testicular ultrasound should be arranged where a testicular tumour is suspected

• Breast imaging — where breast cancer is suspected (particularly with unilateral, hard, or fixed breast tissue), men should be referred to a breast clinic for triple assessment (clinical examination, imaging with ultrasound ± mammography, and biopsy if indicated) in line with NICE NG12

Investigations are guided by NICE NG88 (for PCOS-related hirsutism) and NICE NG12 (for suspected breast malignancy), with a stepwise approach to avoid unnecessary testing whilst ensuring serious pathology is not missed.

Treatment Options and Medications

Hirsutism is treated with lifestyle changes, the combined oral contraceptive pill, spironolactone, or eflornithine cream; gynaecomastia may be managed with watchful waiting, medication review, off-label SERMs such as tamoxifen, or surgery.

Treatment for both conditions depends on the underlying cause, severity of symptoms, and individual patient preferences. Where a specific cause is identified — such as a medication, tumour, or thyroid disorder — addressing that cause is the primary goal.

For hirsutism, management options include:

• Lifestyle modification — weight loss in overweight women with PCOS can significantly reduce androgen levels and improve symptoms

• Combined oral contraceptive pill (COCP) — a common pharmacological option; suppresses ovarian androgen production and increases SHBG. Co-cyprindiol (cyproterone acetate/ethinylestradiol) has additional anti-androgenic properties, but the MHRA restricts its use to women with severe hirsutism or severe acne that has not responded adequately to other treatments. It carries a higher risk of venous thromboembolism (VTE) than standard COCPs and must not be used solely for contraception; full contraindications and precautions are detailed in the Summary of Product Characteristics (SmPC). It should be discontinued three to four cycles after the condition has resolved

• Spironolactone — an aldosterone antagonist with anti-androgenic effects, used off-label for hirsutism in the UK. Because it is teratogenic to a male foetus, effective contraception is essential throughout treatment. Baseline and periodic monitoring of renal function and serum potassium is required, particularly in women also taking ACE inhibitors, angiotensin receptor blockers, or other potassium-sparing agents (BNF)

• Eflornithine 11.5% cream (Vaniqa®) — licensed in the UK for facial hirsutism; inhibits an enzyme involved in hair growth and is applied topically. Prescribers and patients should be aware that UK supply has been intermittently unavailable; current availability should be checked via the Specialist Pharmacy Service (SPS) or local medicines supply notifications before prescribing

• Physical hair removal — laser hair removal, electrolysis, and waxing are effective adjuncts; laser therapy may be available via some NHS trusts for significant cases

For gynaecomastia, treatment options include:

• Watchful waiting — appropriate for physiological or mild cases, particularly in adolescents

• Medication review — discontinuing or substituting causative drugs where clinically safe

• Tamoxifen or raloxifene — selective oestrogen receptor modulators (SERMs) used off-label in the UK for symptomatic gynaecomastia. Evidence supports modest benefit, particularly in early or painful cases. Both carry a risk of VTE and other adverse effects; malignancy must be excluded before use (BNF). Patients should be counselled about the off-label nature of treatment

• Surgical intervention — subcutaneous mastectomy or liposuction may be considered for persistent, distressing gynaecomastia; NHS availability varies by Integrated Care Board (ICB) and is generally subject to local low-value procedures or prior approval policies

If you experience a suspected side effect from any medicine, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Managing Symptoms and Long-Term Outlook

The long-term outlook is generally positive when the underlying cause is treated; PCOS requires ongoing metabolic monitoring, pubertal gynaecomastia usually resolves spontaneously, and psychological support should be offered to all affected individuals.

The long-term outlook for both hirsutism and gynaecomastia is generally positive, particularly when the underlying cause is identified and appropriately managed. However, both conditions can have a meaningful impact on psychological wellbeing, body image, and quality of life, and this dimension of care should not be overlooked.

For women with hirsutism, particularly those with PCOS, long-term management is often necessary rather than curative. Ongoing monitoring is important because PCOS carries associated metabolic risks, including type 2 diabetes, dyslipidaemia, and cardiovascular disease. In line with NICE NG88, regular review should include HbA1c or OGTT, fasting lipid profile, blood pressure, weight, and BMI, with lifestyle advice reinforced at each contact. Hair growth may improve gradually with treatment, but response can take six to twelve months to become apparent, and realistic expectations should be set from the outset. Women taking anti-androgenic treatments should receive appropriate contraception counselling, as some agents are teratogenic.

For men with gynaecomastia, the prognosis depends largely on the cause. Pubertal gynaecomastia resolves spontaneously in the majority of cases. Drug-induced gynaecomastia often improves after the offending agent is withdrawn, though established fibrotic tissue may not fully regress. Where surgery is undertaken, outcomes are generally good, with high patient satisfaction reported in the literature.

Psychological support should be considered for both conditions, as body image concerns, anxiety, and low self-esteem are common. Referral to a clinical psychologist or counsellor may be appropriate. NHS Talking Therapies services are accessible via GP referral or, in many areas, via self-referral — visit the NHS website to find your local service. Patient support organisations — such as Verity (for women with PCOS) — can also provide valuable peer support and information.

In summary, neither hirsutism nor gynaecomastia should be dismissed without proper evaluation. With the right investigations and a tailored management plan, most individuals can achieve meaningful symptom improvement and maintain good long-term health.

Key references: NICE NG88 (Polycystic ovary syndrome: diagnosis and management); NICE NG12 (Suspected cancer: recognition and referral); NHS Hirsutism and Gynaecomastia pages; MHRA/EMC SmPCs for co-cyprindiol, eflornithine cream; BNF monographs for spironolactone, tamoxifen, and raloxifene; Specialist Pharmacy Service (SPS) medicines supply updates.

Frequently Asked Questions